Kestra Medical Technologies (NASDAQ:KMTS – Get Free Report) and Anteris Technologies Global (NASDAQ:AVR – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, profitability, dividends, analyst recommendations, risk and institutional ownership.
Analyst Ratings
This is a summary of recent ratings and recommmendations for Kestra Medical Technologies and Anteris Technologies Global, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Kestra Medical Technologies | 1 | 2 | 5 | 0 | 2.50 |
| Anteris Technologies Global | 1 | 1 | 3 | 0 | 2.40 |
Kestra Medical Technologies presently has a consensus price target of $29.00, indicating a potential upside of 2.46%. Anteris Technologies Global has a consensus price target of $13.75, indicating a potential upside of 151.05%. Given Anteris Technologies Global’s higher probable upside, analysts plainly believe Anteris Technologies Global is more favorable than Kestra Medical Technologies.
Profitability
This table compares Kestra Medical Technologies and Anteris Technologies Global’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Kestra Medical Technologies | -140.43% | -63.83% | -44.76% |
| Anteris Technologies Global | -4,637.48% | -57.15% | -50.73% |
Valuation & Earnings
This table compares Kestra Medical Technologies and Anteris Technologies Global”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Kestra Medical Technologies | $106.73 million | 15.80 | -$131.61 million | ($2.67) | -10.60 |
| Anteris Technologies Global | $1.91 million | 279.56 | -$94.14 million | ($1.61) | -3.40 |
Anteris Technologies Global has lower revenue, but higher earnings than Kestra Medical Technologies. Kestra Medical Technologies is trading at a lower price-to-earnings ratio than Anteris Technologies Global, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Kestra Medical Technologies has a beta of 0.45, suggesting that its share price is 55% less volatile than the S&P 500. Comparatively, Anteris Technologies Global has a beta of 2.02, suggesting that its share price is 102% more volatile than the S&P 500.
Summary
Anteris Technologies Global beats Kestra Medical Technologies on 7 of the 12 factors compared between the two stocks.
About Kestra Medical Technologies
Kestra Medical Technologies is a medical technology company focused on wearable solutions for people at risk of sudden cardiac arrest. Its products combine cardiac monitoring, treatment technology and digital services intended to support patients and their care teams. The company’s flagship product, the ASSURE wearable cardioverter defibrillator, continuously monitors a patient’s heart rhythm and can deliver a treatment shock if it detects a life-threatening arrhythmia. The system also provides alerts and supports remote sharing of patient data with clinicians.
About Anteris Technologies Global
Anteris Technologies Global is a medical technology company focused on developing treatments for structural heart disease, particularly aortic valve conditions. Its work centers on transcatheter heart valve technology, which is designed to replace a damaged valve through a minimally invasive procedure. The company’s lead product is the DurAVR transcatheter heart valve. It is made using Anteris’ ADAPT tissue technology, which processes bovine pericardial tissue for use in medical devices. The valve is designed to resemble the structure and function of a healthy aortic valve.
Receive News & Ratings for Kestra Medical Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kestra Medical Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
